Elicio Therapeutics (ELTX) EBITDA Margin (2020 - 2022)
Elicio Therapeutics' (ELTX) quarterly EBITDA Margin came in at 954.36% in Q2 2022, up 242415.0% YoY from N/an in Q2 2021, and down 8.58% on a QoQ basis from 878.94% in Q1 2022.
Elicio Therapeutics (ELTX) EBITDA Margin (2020 - 2022) Analysis & Trends
Elicio Therapeutics (ELTX) has 3 years of EBITDA Margin data on file, last reported at 954.36% in Q2 2022.
- Quarterly EBITDA Margin rose 242415.0% year-over-year to 954.36% in Q2 2022, while the trailing twelve-month figure through Mar 2023 was 3946.09% (down 383168.0% YoY) and the FY2022 annual result came in at 1031.42%, down 89259.0% from the prior year.
- EBITDA Margin retreated to 954.36% in Q2 2022, from 878.94% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 56.41% in Q4 2021 to a low of 5374.39% in Q1 2021.
- A 3-year average of 2044.03% and a median of 1400.85% in 2020 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2021 — EBITDA Margin sank 100966 bps — and 2022, when it jumped 449545 bps.
- Tracing ELTX's EBITDA Margin over 3 years: stood at 3017.43% in 2020, then soared by 102 bps to 56.41% in 2021, then tumbled by 1792 bps to 954.36% in 2022.
- The last three EBITDA Margin figures came in at 954.36% (Q2 2022), 878.94% (Q1 2022), and 56.41% (Q4 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 17.93% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.36% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.75% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -35.57% |
| 10 | Elicio Therapeutics | 59.08 Mn | 35.58 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | -954.36% |
| Mar 31, 2022 | -878.94% |
| Dec 31, 2021 | 56.41% |
| Sep 30, 2021 | -1,079.32% |
| Jun 30, 2021 | -3,378.52% |
| Mar 31, 2021 | -5,374.39% |
| Dec 31, 2020 | -3,017.43% |
| Sep 30, 2020 | -1,400.85% |
| Jun 30, 2020 | -2,368.86% |